Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- 8-K Current report
- 2.1 Agreement and Plan of Merger, Dated June 17, 2020.
- 3.1 Certificate of Merger
- 3.2 Amended and Restated Certificate of Incorporation
- 3.3 Amended and Restated Bylaws
- 10.1 2020 Stock Option and Incentive Plan
- 10.2 2020 Senior Executive Cash Incentive Bonus Plan
- 10.3 Offer Letter, Dated November 8, 2017, Between Vered Bisker-leib and Compass Therapeutics LLC
- 10.4 Form of Indemnification Agreement (Directors)
- 10.5 Form of Indemnification Agreement (Executive Officers)
- 10.6 Form of Pre-merger Indemnification Agreement (Directors and Executive Officers)
- 10.7 Registration Rights Agreement, Dated June 19, 2020.
- 10.8 Subscription Agreement, Dated June 19, 2020.
- 10.9 Amended and Restated Collaboration Agreement, Dated February 11, 2015.
- 10.10 Loan and Security Agreement, Dated March 30, 2018.
- 10.11 First Amendment to Loan and Security Agreement, Dated September 26, 2018.
- 10.12 Second Amendment to Loan and Security Agreement, Dated March 8, 2019.
- 10.13 Third Amendment to Loan and Security Agreement, Dated October 29, 2019.
- 10.14 Sublease Agreement, Dated July 29, 2016.
- 10.15 Sublease Modification Agreement, Dated January 17, 2018.
- 16.1 Letter from Raich Ende Malter & Co. LLP
- 21.1 Subsidiaries of the Registrant
- 99.1 Audited Financial Statements of Compass Therapeutics, LLC As of and for the Fiscal Years Ended December 31, 2019 and 2018
- 99.2 Unaudited Financial Statements of Compass Therapeutics, LLC As of and for the Quarterly Period Ended March 31, 2020
- 99.3 Unaudited Pro Forma Combined Financial Statements As of and for the Fiscal Year Ended December 31, 2019
- 99.4 Press Release Dated June 23, 2020
CMPX similar filings
Filing view
External links
Exhibit 16.1
June 23, 2020
Securities and Exchange Commission
100 F Street NE
Washington, D.C. 20549
Ladies and Gentlemen:
We have read Item 4.01 of the Current Report on Form 8-K dated June 23, 2020 of Compass Therapeutics, Inc. and are in agreement with the statements in the paragraphs within that Item as they relate to our firm. We have no basis to agree or disagree with other statements of the registrant contained therein.
Respectfully submitted,
/s/ Raich Ende Malter & Co. LLP
New York, New York